## **Zhouguang Hui**

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5836353/zhouguang-hui-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

62 487 13 19 g-index

71 734 4.3 avg, IF 3.49 L-index

#	Paper	IF	Citations
62	Anlotinib Enhances the Antitumor Activity of High-Dose Irradiation Combined with Anti-PD-L1 by Potentiating the Tumor Immune Microenvironment in Murine Lung Cancer Oxidative Medicine and Cellular Longevity, 2022, 2022, 5479491	6.7	O
61	Local Therapy Combined With First-Line EGFR Tyrosine Kinase Inhibitor Achieves Favorable Survival in Patients With EGFR-Mutant Metastatic Non-Small Cell Lung Cancer <i>Clinical Medicine Insights: Oncology</i> , <b>2022</b> , 16, 11795549221080347	1.8	О
60	Chemoradiotherapy is an alternative choice for patients with primary mediastinal seminoma <i>Radiation Oncology</i> , <b>2022</b> , 17, 58	4.2	
59	MiR-323a-3p acts as a tumor suppressor by suppressing FMR1 and predicts better esophageal squamous cell carcinoma outcome <i>Cancer Cell International</i> , <b>2022</b> , 22, 140	6.4	1
58	A Nomogram for Predicting Brain Metastasis in IIIA-N2 Non-Small Cell Lung Cancer After Complete Resection: A Competing Risk Analysis <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 781340	5.3	O
57	Survival of Neoadjuvant and Adjuvant Therapy Compared With Surgery Alone for Resectable Esophageal Squamous Cell Carcinoma: A Systemic Review and Network Meta-Analysis. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 728185	5.3	1
56	Recurrence risk stratification based on a competing-risks nomogram to identify patients with esophageal cancer who may benefit from postoperative radiotherapy <i>Therapeutic Advances in Medical Oncology</i> , <b>2021</b> , 13, 17588359211061948	5.4	O
55	Additional Radiotherapy With or Without Chemotherapy Following Endoscopic Resection for Stage I Esophageal Carcinoma: A Pilot Study. <i>Technology in Cancer Research and Treatment</i> , <b>2021</b> , 20, 153303	382 <sup>7</sup> 110	048051
54	Endostar (rh-endostatin) improves efficacy of concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: A systematic review and meta-analysis. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 3208-321	5 <sup>3.2</sup>	3
53	Role of modern neoadjuvant chemoradiotherapy in locally advanced thymic epithelial neoplasms. <i>Tumori</i> , <b>2021</b> , 107, 407-415	1.7	O
52	A validation study on the lung immune prognostic index for prognostic value in patients with locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2021</b> , 156, 244-250	5.3	3
51	Risk of cardiac-related mortality in stage IIIA-N2 non-small cell lung cancer: Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 1358-1365	3.2	2
50	Intensity modulated radiation therapy may improve survival for tracheal-bronchial adenoid cystic carcinoma: A retrospective study of 133 cases. <i>Lung Cancer</i> , <b>2021</b> , 157, 116-123	5.9	1
49	Postoperative radiotherapy for pathological stage IIIA-N2 non-small cell lung cancer with positive surgical margins. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 227-234	3.2	3
48	The Optimal Treatment for Resectable Esophageal Cancer: A Network Meta-Analysis of 6168 Patients. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 628706	5.3	5
47	Epithelial circulating tumor cells with a heterogeneous phenotype are associated with metastasis in NSCLC. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2021</b> , 1	4.9	2
46	Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial. <i>JAMA Oncology</i> , <b>2021</b> , 7, 1178-1185	13.4	23

45	A novel angular dependency model for MatriXX response and its application to true composite dose verification for IMRT plans. <i>Journal of Applied Clinical Medical Physics</i> , <b>2021</b> , 22, 120-135	2.3	1
44	Clinical outcomes and radiation pneumonitis after concurrent EGFR-tyrosine kinase inhibitors and radiotherapy for unresectable stage III non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2021</b> , 12, 814-823	3.2	4
43	Development and validation of a prediction model using molecular marker for long-term survival in unresectable stage III non-small cell lung cancer treated with chemoradiotherapy <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	2
42	Postoperative radiotherapy improves survival of patients with ypN2 non-small cell lung cancer after neoadjuvant chemotherapy followed by surgery - A propensity score matching study of the Surveillance, Epidemiology, and End Results database <i>Thoracic Cancer</i> , <b>2021</b> ,	3.2	1
41	Do Higher Radiation Doses with Concurrent Chemotherapy in the Definitive Treatment of Esophageal Cancer Improve Outcomes? A Meta-Analysis and Systematic Review. <i>Journal of Cancer</i> , <b>2020</b> , 11, 4605-4613	4.5	5
40	Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials. <i>Thoracic Cancer</i> , <b>2020</b>	3.2	5
39	Evaluation of Privacy Risks of PatientsTData in China: Case Study. JMIR Medical Informatics, 2020, 8, e13	30,46	2
38	Going Beyond Results of the PEMBRO-RT Trial. <i>JAMA Oncology</i> , <b>2020</b> , 6, 160-161	13.4	
37	Aspirin overcomes cisplatin resistance in lung cancer by inhibiting cancer cell stemness. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 3117-3125	3.2	2
36	Combined neat model for the prognosis of postoperative stage III-N2 non-small cell lung cancer. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2610-2617	3.2	1
35	High vs. Low Radiation Dose of Concurrent Chemoradiotherapy for Esophageal Carcinoma With Modern Radiotherapy Techniques: A Meta-Analysis. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 1222	5.3	8
34	Multivariate gene expression-based survival predictor model in esophageal adenocarcinoma. <i>Thoracic Cancer</i> , <b>2020</b> , 11, 2896-2908	3.2	2
33	Debulking Surgery Plus Radiation: Treatment Choice for Unresectable Stage III Thymic Carcinoma. <i>Thoracic and Cardiovascular Surgeon</i> , <b>2020</b> , 68, 440-445	1.6	2
32	Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial. <i>BMC Cancer</i> , <b>2020</b> , 20, 278	4.8	2
31	Prospective Exploratory Study of the Clinical Significance of Circulating Tumor Cells in Patients With Small Cell Lung Cancer Exposed to Prophylactic Cranial Irradiation. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 575394	5.3	1
30	Trends of Postoperative Radiotherapy for Completely Resected Non-small Cell Lung Cancer in China: A Hospital-Based Multicenter 10-Year (2005-2014) Retrospective Clinical Epidemiological Study. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 786	5.3	O
29	Treatment Optimization for Brain Metastasis from Anaplastic Lymphoma Kinase Rearrangement Non-Small-Cell Lung Cancer. <i>Oncology Research and Treatment</i> , <b>2019</b> , 42, 599-606	2.8	9
28	PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population. <i>Diagnostic Pathology</i> , <b>2019</b> , 14, 6	3	17

27	Postoperative radiotherapy is effective in improving survival of patients with stage pIII-N2 non-small-cell lung Cancer after pneumonectomy. <i>BMC Cancer</i> , <b>2019</b> , 19, 478	4.8	10
26	Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and conventional intensity-modulated radiotherapy in locally advanced non-small-cell lung cancer: a retrospective study. <i>Radiation Oncology</i> , <b>2019</b> , 14, 106	4.2	10
25	The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases. <i>Journal of Cancer</i> , <b>2019</b> , 10, 1985-1990	4.5	6
24	Tumor Mutation Load: A Novel Independent Prognostic Factor in Stage IIIA-N2 Non-Small-Cell Lung Cancer. <i>Disease Markers</i> , <b>2019</b> , 2019, 3837687	3.2	5
23	Comparison of hyper- and hypofractionated radiation schemes with IMRT technique in small cell lung cancer: Clinical outcomes and the introduction of extended LQ and TCP models. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 136, 98-105	5.3	6
22	Exosome-derived miR-339-5p mediates radiosensitivity by targeting Cdc25A in locally advanced esophageal squamous cell carcinoma. <i>Oncogene</i> , <b>2019</b> , 38, 4990-5006	9.2	43
21	A propensity-score matching analysis comparing long-term survival of surgery alone and postoperative treatment for patients in node positive or stage III esophageal squamous cell carcinoma after R0 esophagectomy. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 140, 159-166	5.3	10
20	Survival benefit of radiotherapy in metastatic esophageal cancer: a population-based study <i>Translational Cancer Research</i> , <b>2019</b> , 8, 1074-1085	0.3	O
19	Effect of Concurrent Chemoradiation With Celecoxib vs Concurrent Chemoradiation Alone on Survival Among Patients With Non-Small Cell Lung Cancer With and Without Cyclooxygenase 2 Genetic Variants: A Phase 2 Randomized Clinical Trial. <i>JAMA Network Open</i> , <b>2019</b> , 2, e1918070	10.4	7
18	HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer. <i>Radiotherapy and Oncology</i> , <b>2019</b> , 131, 27-34	5.3	16
17	Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients. <i>Journal of Cancer</i> , <b>2018</b> , 9, 584-593	4.5	20
16	A Single-Center Analysis of the Treatment and Prognosis of Patients With Thymic Carcinoma. <i>Annals of Thoracic Surgery</i> , <b>2017</b> , 104, 1718-1724	2.7	15
15	Effect of socioeconomic status on stage at diagnosis of lung cancer in a hospital-based multicenter retrospective clinical epidemiological study in China, 2005-2014. <i>Cancer Medicine</i> , <b>2017</b> , 6, 2440-2452	4.8	14
14	Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer. <i>Radiation Oncology</i> , <b>2017</b> , 12, 195	4.2	7
13	BRAIN study: it is hard to draw a conclusion. <i>Lancet Respiratory Medicine,the</i> , <b>2017</b> , 5, e33	35.1	1
12	MicroRNA-Related Polymorphisms in PI3K/Akt/mTOR Pathway Genes Are Predictive of Limited-Disease Small Cell Lung Cancer Treatment Outcomes. <i>BioMed Research International</i> , <b>2017</b> , 2017, 6501385	3	9
11	The role of postoperative radiotherapy (PORT) in combined small cell lung cancer (C-SCLC). <i>Oncotarget</i> , <b>2017</b> , 8, 48922-48929	3.3	6
10	Intensity-Modulated Radiation Therapy May Improve Local-Regional Tumor Control for Locally Advanced Non-Small Cell Lung Cancer Compared With Three-Dimensional Conformal Radiation Therapy. <i>Oncologist</i> , <b>2016</b> , 21, 1530-1537	5.7	22

## LIST OF PUBLICATIONS

Ş	9	A Proposal for Combination of Lymph Node Ratio and Anatomic Location of Involved Lymph Nodes for Nodal Classification in Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , <b>2016</b> , 11, 1565-73	8.9	20	
8	3	Selection of proper candidates with resected pathological stage IIIA-N2 non-small cell lung cancer for postoperative radiotherapy. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 346-53	3.2	17	
7	7	Role of radiotherapy in treating patients with primary malignant mediastinal non-seminomatous germ cell tumor: A 21-year experience at a single institution. <i>Thoracic Cancer</i> , <b>2015</b> , 6, 399-406	3.2	16	
e	5	Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapyretrospective analysis of 203 cases. <i>BMC Cancer</i> , <b>2015</b> , 15, 715	4.8	11	
	5	Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2014</b> , 89, 330-7	4	36	
4	4	Prognosis of R1-resection at the bronchial stump in patients with non-small cell lung cancer. <i>Chinese Medical Journal</i> , <b>2014</b> , 127, 2918-23	2.9	2	
3	3	Nimotuzumab combined with radiotherapy on esophageal cancer: Preliminary study of a phase II clinical trial <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, e14511-e14511	2.2		
2	<u>2</u>	Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution. <i>Oncologist</i> , <b>2011</b> , 16, 641-50	5.7	55	
1	Ĺ	Survey on use of postmastectomy radiotherapy for breast cancer in China. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2006</b> , 66, 1135-42	4	13	